US Preimplantation Genetic Testing Market Research Report: By Application (Diagnostic Testing, Carrier Screening, Embryo Selection), By Technique (Polymerase Chain Reaction, Next Generation Sequencing, Fluorescence In Situ Hybridization, Single Nucleotide Polymorphism), By End Use (Fertility Clinics, Research Laboratories, Hospitals) and By Client Type (Individuals, Healthcare Providers, Healthcare Institutions) - Forecast to 2035

US Preimplantation Genetic Testing Market Overview:

As per MRFR analysis, the US Preimplantation Genetic Testing Market Size was estimated at 413.7 (USD Million) in 2023. The US Preimplantation Genetic Testing Market Industry is expected to grow from 443.1(USD Million) in 2024 to 945 (USD Million) by 2035. The US Preimplantation Genetic Testing Market CAGR (growth rate) is expected to be around 7.128% during the forecast period (2025 - 2035).

Key US Preimplantation Genetic Testing Market Trends Highlighted

The US Preimplantation Genetic Testing Market is experiencing notable trends driven by various societal and technological factors. One key market driver is the growing awareness and acceptance of genetic testing among prospective parents, driven largely by educational initiatives and advancements in reproductive health technologies. The increase in demand for in-vitro fertilization (IVF) procedures further fuels the need for preimplantation genetic testing, as these tests help identify potential genetic disorders in embryos, ensuring healthier outcomes for pregnancies. Additionally, insurance coverage policies in several states support this trend by making genetic testing more affordable for patients, thereby promoting its adoption.Opportunities to be explored in this market include the expansion of genetic testing services to a broader demographic. With rising health consciousness and increasing focus on personalized medicine, integrating preimplantation genetic testing into broader maternal health initiatives could enhance service reach and accessibility. Furthermore, advancements in artificial intelligence and machine learning have the potential to improve diagnostic capabilities, making testing more reliable and efficient, which is an area that can be leveraged for growth. Recent trends also indicate that there is a push towards more informed decision-making processes among patients regarding their reproductive choices.Dialogue on genetic health is becoming more prevalent, leading to increased consultations around preimplantation genetic testing. Innovations in testing methods and the development of non-invasive techniques are likely to enhance the user experience and offer more options for patients. Overall, as the landscape evolves, there is a clearer alignment between consumer demand and technological advancements that are shaping the future of the Preimplantation Genetic Testing Market in the US.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Preimplantation Genetic Testing Market Drivers

Rising Awareness of Genetic Disorders

The increasing awareness regarding genetic disorders in the United States is a prominent driver for the US Preimplantation Genetic Testing Market Industry. With a shift towards preventive healthcare, many prospective parents are seeking testing to understand their genetic risks. According to the Centers for Disease Control and Prevention (CDC), about 1 in 33 babies is born with a birth defect, highlighting the necessity for genetic testing options like Preimplantation Genetic Testing to mitigate risks.Organizations such as the National Society of Genetic Counselors (NSGC) are playing a key role by providing educational resources, thereby promoting awareness and increasing demand for genetic testing services. This growing awareness not only aids patients in making informed reproductive choices but also fuels market growth in the US preimplantation genetic testing sector.

Advancements in Genetic Testing Technology

Technological advancements in genetic testing are significantly influencing the US Preimplantation Genetic Testing Market Industry. With the rapid evolution of techniques such as next-generation sequencing and array comparative genomic hybridization, more precise and quicker results are achievable. The American College of Obstetricians and Gynecologists (ACOG) has noted that these advancements improve the reliability of genetic testing, enabling clinicians to detect genetic anomalies more effectively.As technology continues to advance, it is expected that the scope and accuracy of preimplantation genetic tests will expand, leading to higher adoption rates among fertility clinics across the United States.

Increase in Adoption of Assisted Reproductive Technologies

The growing use of Assisted Reproductive Technologies (ART) in the US is a critical driver for the US Preimplantation Genetic Testing Market Industry. According to the Society for Assisted Reproductive Technology (SART), more than 330,000 ART cycles were performed in the United States in 2020, with a notable percentage of these involving preimplantation genetic testing. This trend can be attributed to increasing infertility rates and changing societal attitudes toward family planning.As more individuals opt for ART, the integration of preimplantation genetic testing is becoming a standard practice to ensure healthier outcomes for neonates, driving substantial growth in the market.

Legislative Support for Genetic Testing

The legislative landscape in the United States has become increasingly supportive of genetic testing initiatives, positively impacting the US Preimplantation Genetic Testing Market Industry. Various states have enacted laws aimed at expanding insurance coverage for genetic testing, thereby making these services more accessible to a broader population. For instance, the Genetic Information Nondiscrimination Act (GINA) provides protection against discrimination based on genetic information, which minimizes the uncertainty surrounding genetic testing for prospective parents.Support from government policies has a favorable impact on market growth as it facilitates wider acceptance and utilization of preimplantation genetic testing, paving the way for a more robust industry landscape.

US Preimplantation Genetic Testing Market Segment Insights:

Preimplantation Genetic Testing Market Application Insights

The US Preimplantation Genetic Testing Market undergoes substantial transformation, particularly within the Application segment, which encompasses Diagnostic Testing, Carrier Screening, and Embryo Selection. Diagnostic Testing plays a pivotal role, facilitating early identification of genetic disorders or chromosomal abnormalities, thereby guiding couples in their reproductive decisions. This aspect is crucial as it allows parents to make informed choices regarding embryo selection, prioritizing healthier genetic profiles. In Carrier Screening, advancements aim to identify potential carriers of genetic conditions, enabling proactive measures in family planning.This practice is gaining momentum as awareness increases regarding genetic conditions prevalent among various populations in the US, making it a key consideration for couples planning to conceive. Embryo Selection, another significant component of this market segment, underscores the science of selecting embryos with the highest likelihood of successful implantation and healthy development. This precision not only enhances chances for successful pregnancies but also reduces the emotional and financial burden associated with infertility treatments.The growing trend towards personalized medicine further accentuates the importance of these applications as patients increasingly seek targeted genetic insights tailored to their familial backgrounds. The US Preimplantation Genetic Testing Market is expected to see expanded adoption of these applications due to a combination of rising fertility rates, technological advancements, and increasing public awareness of genetic health issues. Furthermore, regulatory support and improvements in healthcare accessibility are anticipated to foster continued growth, paving the way for enhanced reproductive health outcomes across various demographics in the US..

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Preimplantation Genetic Testing Market Technique Insights

The US Preimplantation Genetic Testing Market is characterized by various techniques that play a crucial role in advancing reproductive genetics. Among these techniques, Polymerase Chain Reaction (PCR) is recognized for its rapid amplification of DNA, making it essential for detecting genetic disorders at early stages. Next Generation Sequencing (NGS) has gained prominence due to its ability to provide comprehensive genetic profiling, allowing for the identification of multiple genetic conditions simultaneously, thus streamlining the testing process.Fluorescence In Situ Hybridization (FISH) offers precise visualization of chromosomes, making it invaluable in diagnosing chromosomal abnormalities during preimplantation stages. Additionally, Single Nucleotide Polymorphism (SNP) analysis aids in understanding genetic variations relevant to hereditary diseases. Together, these technologies enhance the accuracy and reliability of preimplantation genetic testing, offering families informed choices in reproductive health. The ongoing advancements and integration of these techniques are expected to substantially impact the growth trajectory of the US Preimplantation Genetic Testing Market, with rising awareness and increasing investments in Research and Development driving innovation and accessibility in genetic testing services.

Preimplantation Genetic Testing Market End Use Insights

The US Preimplantation Genetic Testing Market focuses on key End Use sectors, including Fertility Clinics, Research Laboratories, and Hospitals, each playing a critical role in the adoption and implementation of genetic testing technologies. Fertility Clinics dominate this segment as they provide essential services to couples undergoing in-vitro fertilization, benefiting from advancements in genetic testing to improve success rates and reduce the risk of genetic disorders. Research Laboratories contribute significantly by driving innovation and developing new techniques, often leading to breakthroughs in Preimplantation Genetic Testing methods.Hospitals also serve a vital function, integrating genetic testing into broader patient care pathways, enabling more personalized treatment options. The collaborative efforts among these segments reflect the growing trend toward personalized medicine, utilizing Preimplantation Genetic Testing to enhance reproductive outcomes. Furthermore, increasing awareness, advancements in technology, and supportive policies contribute to market growth in these areas, presenting ample opportunities for development and collaboration within the US Preimplantation Genetic Testing Market.

Preimplantation Genetic Testing Market Client Type Insights

The Client Type segment of the US Preimplantation Genetic Testing Market reveals critical insights into the diverse groups that utilize these genetic testing services. Individuals, representing prospective parents primarily concerned with hereditary conditions, form a significant part of the market, driving the need for efficient preimplantation genetic testing solutions. Healthcare Providers, including specialists and clinicians, play an essential role by recommending genetic testing as part of fertility treatments, which heightens patient awareness and demand.Meanwhile, Healthcare Institutions such as hospitals and fertility clinics are crucial in offering these services on a broader scale, enabling access to advanced diagnostic capabilities. With an increasing focus on personalized medicine and advancements in reproductive technologies, this segment showcases a growing trend towards comprehensive genetic screening as part of reproductive planning. The ongoing evolution of genetic testing methodologies and patient education also drives significant growth within the Client Type categorizations, indicating a promising future for the industry.The interplay of these groups illustrates a dynamic ecosystem where awareness, accessibility, and advancements in technology enhance the overall landscape of genetic testing in the US.

US Preimplantation Genetic Testing Market Key Players and Competitive Insights:

The US Preimplantation Genetic Testing Market is characterized by a dynamic landscape shaped by technological advancements, growing consumer awareness of genetic disorders, and increasing acceptance of assisted reproductive technologies. This market is witnessing significant competition among key players who are developing innovative solutions aimed at enhancing the accuracy and efficiency of preimplantation genetic diagnosis and testing. The increasing prevalence of genetic abnormalities and the rising demand for in vitro fertilization have catalyzed market growth, resulting in a wave of investments that focus on research and development. Market participants are vying for a competitive edge by forging strategic partnerships, enhancing their product portfolios, and expanding their service offerings to capture a larger share of this burgeoning market. As advancements in genomics continue to evolve, the competitive landscape will likely continue to become more intricate, with new players emerging and established companies consolidating their positions.Illumina stands out prominently in the US Preimplantation Genetic Testing Market due to its robust technological capabilities and extensive product portfolio. The company specializes in next-generation sequencing technologies, enabling high-throughput genetic analyses that are critical for the accurate diagnosis of preimplantation genetic conditions. Illumina's strong reputation in the genomics space helps in establishing credibility among healthcare providers and patients alike. The company’s significant investments in research and development bolster its competitive advantage, allowing it to stay ahead in a rapidly evolving market. Illumina’s continuous efforts to innovate have led to the introduction of advanced solutions that cater to the needs of fertility clinics and reproductive specialists, further embedding its presence in the US market. The company has strategically positioned itself through collaborations with fertility clinics and researchers, enhancing its visibility and reinforcing its status as a leader in preimplantation genetic testing.LabCorp also plays a pivotal role in the US Preimplantation Genetic Testing Market, offering a comprehensive range of genetic testing services. The company is recognized for its extensive laboratory network and commitment to providing accurate and timely testing solutions. LabCorp’s portfolio includes key services related to preimplantation genetic testing, with the integration of cutting-edge technologies that enhance diagnostic capabilities. The firm's strong presence across the US healthcare landscape is supported by strategic mergers and acquisitions, allowing it to expand its geographical reach and strengthen its service offerings in reproductive health. LabCorp’s established relationships with healthcare providers and its commitment to quality assurance resonate with both clinicians and patients, reinforcing its market position. The integration of advanced methodologies in genetic analysis sets LabCorp apart, ensuring that it remains competitive as technology progresses within the realm of preimplantation genetic testing.

Key Companies in the US Preimplantation Genetic Testing Market Include:

Illumina

LabCorp

Fulgent Genetics

Genomic Health

Myriad Genetics

PerkinElmer

Thermo Fisher Scientific

Sema4

Quest Diagnostics

Roche

Cleveland Clinic

Invitae

CooperSurgical

Natera

US Preimplantation Genetic Testing Market Industry Developments

The US Preimplantation Genetic Testing Market has witnessed significant developments recently, particularly with advancements in technology and genetic testing services. Companies like Illumina and Thermo Fisher Scientific continue to enhance their offerings in next-generation sequencing, impacting the market positively. LabCorp and Quest Diagnostics are ramping up their genetic screening services in response to increased consumer demand for personalized medicine. In terms of mergers and acquisitions, in September 2023, Illumina completed its acquisition of GRAIL, enhancing its capabilities in multi-cancer early detection, which strengthens its position in the preimplantation testing space. Additionally, in July 2023, Myriad Genetics announced its acquisition of Sema4’s GenomeFirst platform, expanding its portfolio in genetic testing. The increasing prevalence of genetic disorders and rising awareness among patients have driven market growth, with genetic testing becoming a crucial part of assisted reproductive technology. Moreover, the US witnessed a notable increase in investment in companies like Natera and CooperSurgical, emphasizing Research and Development initiatives in genetic testing. Overall, the landscape of the US Preimplantation Genetic Testing Market is rapidly evolving, reflecting the growing importance of genetic insights in reproductive health.

US Preimplantation Genetic Testing Market Segmentation Insights

Preimplantation Genetic Testing Market Application Outlook

Diagnostic Testing

Carrier Screening

Embryo Selection

Preimplantation Genetic Testing Market Technique Outlook

Polymerase Chain Reaction

Next Generation Sequencing

Fluorescence In Situ Hybridization

Single Nucleotide Polymorphism

Preimplantation Genetic Testing Market End Use Outlook

Fertility Clinics

Research Laboratories

Hospitals

Preimplantation Genetic Testing Market Client Type Outlook

Individuals

Healthcare Providers

Healthcare Institutions

Report Scope:

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	413.7(USD Million)
MARKET SIZE 2024	443.1(USD Million)
MARKET SIZE 2035	945.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.128% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Illumina, LabCorp, Fulgent Genetics, Genomic Health, Myriad Genetics, PerkinElmer, Thermo Fisher Scientific, Sema4, Quest Diagnostics, Roche, Cleveland Clinic, Invitae, CooperSurgical, Natera
SEGMENTS COVERED	Application, Technique, End Use, Client Type
KEY MARKET OPPORTUNITIES	Increasing infertility rates, Rising awareness of genetic disorders, Technological advancements in testing, Expansion of IVF procedures, Growing demand for personalized medicine
KEY MARKET DYNAMICS	Rising infertility rates, Advancements in technology, Increasing awareness and acceptance, Government support and funding, Ethical and regulatory considerations
COUNTRIES COVERED	US